Breaking News

Lonza, BioWa Ink License Pact with Pfizer

July 30, 2013

Will use POTELLIGENT CHOK1SV cell line

BioWa, Inc. and Lonza have entered into a research agreement with Pfizer for the use of their POTELLIGENT CHOK1SV cell line in the R&D of multiple antibodies in Pfizer’s pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT technology with Lonza’s GS Gene Expression System, which includes the host cell line, CHOK1SV.
 
“We are pleased that the core value of POTELLIGENT Technology has been recognized by a global pharmaceutical company such as Pfizer, and are excited to work together with Pfizer on their innovative antibody research pipelines.” said Yasunori Yamaguchi, Ph.D., president and chief executive officer of BioWa.
 
“The GS System and the CHOK1SV Cell Line continue to be a gold standard for therapeutic antibody development.  We are proud to be able to support Pfizer with this technology for their ongoing development portfolio.” said Karen Fallen, vice president, head of licensing, Lonza Custom Development Services.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems